Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 126,720.81 | 99,072.63 | 20,736.13 | 2,764.80 | 1,610.88 | 4,992.00 | 1,844.35 | 133.12 |
Analyst estimates 2024–2026 Powerpack |
|||
| High | — | — | 1,785,714.25 | 468,867.00 | 385,000.88 | 32,256.21 | 8,025.60 | 25,344.00 | 6,643.20 | 6,374.40 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 15 | 11 | 5 | 6 | 10 | 16 | 16 | 16 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.14 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | 2 | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | — | 100.00 | — | — | 0.00 | 100.00 | |||||
| EBT | — | — | (8) | (12) | (3) | (51) | (19) | (66) | (74) | (38) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | (13,668.00) | 0.00 | 0.00 | 0.00 | (1,719.56) | |||||
| Net income | — | — | (7) | 0 | (3) | (51) | (19) | (66) | (74) | (38) | |||||
| Depreciation | — | — | 0 | 0 | 0 | — | 0 | 7 | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 70.75 | 0.00 | 0.00 | 0.00 | 57.52 | ||||
| Earnings | — | — | (131,591.00) | 2,308.62 | (4,333.99) | (9,686.49) | (1,652.85) | (2,806.01) | (2,657.53) | (989.44) | |||||
| Cash flow | — | — | (2.11) | (105,710.00) | (1,976.25) | (3,642.45) | (1,802.84) | (2,076.06) | (2,223.97) | (624.33) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (2.12) | (105,710.00) | (1,976.25) | (3,642.45) | (1,802.84) | (2,076.06) | (2,223.97) | (624.33) | |||||
| Book value | — | — | (1.15) | 43,710.00 | (5,882.50) | (1.32) | 221.72 | 2,428.94 | (383.07) | (874.93) | |||||
| Shares, m | — | — | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | — | — | 0.00 | ||||
| P/S | — | — | — | — | — | 5.75 | — | — | — | 3.07 | |||||
| P/B | — | — | — | — | — | 0.00 | — | — | — | 0.00 | |||||
| EV/Sales | — | — | — | — | — | 3.66 | — | — | — | 2.30 | |||||
| EV/FCF | — | — | — | — | — | (0.90) | — | — | — | (0.21) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (14) | (11) | (2) | (19) | (21) | (49) | (62) | (24) | ||||
| Capex | — | — | 0 | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | (14) | (11) | (2) | (19) | (21) | (49) | (62) | (24) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (8) | 5 | (5) | 0 | 10 | 75 | (2) | (34) | ||||
| Total debt | — | — | 7 | — | 2 | — | 7 | 18 | 8 | — | |||||
| Net debt | — | — | (2) | (6) | 0 | (10) | (8) | (61) | (7) | (4) | |||||
| Shareholders’ equity | — | — | (8) | 4 | (5) | 0 | 3 | 57 | (11) | (34) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (119.11) | 5.63 | (100.77) | (908.21) | (133.62) | (130.80) | (138.42) | (269.01) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 85.14 | (20.41) | 2,074.63 | 2,175.05 | (1,489.36) | (220.55) | (314.84) | 171.72 | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Jun 2024
Charts ten years each
Seelos Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | −12.97% (below 0%: shrinking) | — | 0.00% | Compare |
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LYRA Lyra Therapeutics, Inc. | $870.0K | — (loss-making) | — (loss-making) | −96.65% (below 0%: shrinking) | n/m | +45.44% (above 0%: growing) | 100.00% | (101,685.71%) | Compare |
| BTTX Better Therapeutics, Inc. | $850.0K | — (loss-making) | — | — | n/m | +20.43% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SEELQ Seelos Therapeutics, Inc. | $700.0K | — (loss-making) | — (loss-making) | +11.90% (above 0%: growing) | n/m | +83.54% (above 0%: growing) | 100.00% | (834.84%) | |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $640.0K | 0.0× | — (loss-making) | — | n/m | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | Compare |
| Median of peers | $920.0K | — | — | −65.98% | — | +10.22% | 0.00% | 0.00% |
Seelos Therapeutics, Inc. (SEELQ) key facts
- Seelos Therapeutics, Inc. (SEELQ) is a Biotechnology company in the Healthcare sector.
- Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million.
- Return on equity was 171.7% and debt-to-equity 0.00.
- Its Altman Z-score is −96.86 (distress zone) for fiscal 2023.